Brain-derived neurotrophic factor and TrkB expression in the "oldest-old," the 90+ Study: Correlation with cognitive status and levels of soluble amyloid-beta

Neurobiology of Aging

Volumn 36, Issue 12, 2015, Pages 3130-3139

  Michalski, Bernadeta ^a   Corrada, Maria M ^b,c   Kawas, Claudia H ^c   Fahnestock, Margaret ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Alzheimer's disease; Amyloid beta; BDNF; Human postmortem; Tau; TrkB

Indexed keywords

AMYLOID BETA PROTEIN; BRAIN DERIVED NEUROTROPHIC FACTOR; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; MESSENGER RNA; TAU PROTEIN; TROPOMYOSIN; AMYLOID BETA-PROTEIN (1-42); BRAIN-DERIVED NEUROTROPHIC FACTOR, HUMAN; ISOPROTEIN; MEMBRANE PROTEIN; PEPTIDE FRAGMENT; PROTEIN TYROSINE KINASE; TROPOMYOSIN-RELATED KINASE-B, HUMAN;

AGED; ALZHEIMER DISEASE; ARTICLE; COGNITION; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; FEMALE; GEL ELECTROPHORESIS; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; NEUROPSYCHOLOGICAL TEST; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; VERY ELDERLY; WESTERN BLOTTING; AGING; BRAIN; GENE EXPRESSION; GENETICS; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY;

AGED, 80 AND OVER; AGING; AMYLOID BETA-PEPTIDES; BRAIN; BRAIN-DERIVED NEUROTROPHIC FACTOR; COGNITION; FEMALE; GENE EXPRESSION; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; NEUROPSYCHOLOGICAL TESTS; PEPTIDE FRAGMENTS; PHOSPHORYLATION; PROTEIN ISOFORMS; PROTEIN-TYROSINE KINASES; RNA, MESSENGER; TAU PROTEINS;

EID: 84947026117     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2015.08.022     Document Type: Article

References (75)

1. Allen S.J., Wilcock G.K., Dawbarn D. Profound and selective loss of catalytic TrkB immunoreactivity in Alzheimer's disease. Biochem. Biophys. Res. Commun. 1999, 264:648-651.
2. Diagnostic and statistical manual of mental disorders: DSM-IV 1994, American Psychiatric Association, American Psychiatric Association, Washington, DC. 4th ed.
3. Arriagada P.V., Growdon J.H., Hedley-Whyte E.T., Hyman B.T. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology 1992, 42:631-639.
4. Benilova I., Karran E., De Strooper B. The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes, Nat. Neurosci 2012, 15:349-357.
5. Bennett D.A., Schneider J.A., Wilson R.S., Bienias J.L., Arnold S.E. Neurofibrillary tangles mediate the association of amyloid load with clinical Alzheimer disease and level of cognitive function. Arch. Neurol. 2004, 61:378-384.
6. Berg L., McKeel D.W., Miller J.P., Storandt M., Rubin E.H., Morris J.C., Baty J., Coats M., Norton J., Goate A.M., Price J.L., Gearing M., Mirra S.S., Saunders A.M. Clinicopathologic studies in cognitively healthy aging and Alzheimer's disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype. Arch. Neurol. 1998, 55:326-335.
7. Blurton-Jones M., Kitazawa M., Martinez-Coria H., Castello N.A., Müller F.J., Loring J.F., Yamasaki T.R., Poon W.W., Green K.N., LaFerla F.M. Neural stem cells improve cognition via BDNF in a transgenic model of Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:13594-13599.
8. Braak H., Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol. 1991, 82:239-259.
9. Braak H., Braak E., Bohl J. Staging of Alzheimer-related cortical destruction. Eur. Neurol. 1993, 33:403-408.
10. Bruner E., Jacobs H.I. Alzheimer's disease: the downside of a highly evolved parietal lobe?. J. Alzheimers Dis. 2013, 35:227-240.
11. Buée L., Bussière T., Buée-Scherrer V., Delacourte A., Hof P.R. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res. Brain Res. Rev. 2000, 33:95-130.
12. Castellani R.J., Lee H.G., Zhu X., Nunomura A., Perry G., Smith M.A. Neuropathology of Alzheimer disease: pathognomonic but not pathogenic. Acta Neuropathol. (Berl) 2006, 111:503-509.
13. Connor B., Young D., Lawlor P., Gai W., Waldvogel H., Faull R.L., Dragunow M. Trk receptor alterations in Alzheimer's disease. Brain Res. Mol. Brain Res. 1996, 42:1-17.
14. Connor B., Young D., Yan Q., Faull R.L., Synek B., Dragunow M. Brain-derived neurotrophic factor is reduced in Alzheimer's disease. Brain Res. Mol. Brain Res. 1997, 49:71-81.
15. Corrada M.M., Berlau D.J., Kawas C.H. A Population-Based Clinicopathological Study in the Oldest-Old: The 90+ Study. Curr. Alzheimer Res. 2012, 9:709-717.
16. DeKosky S.T., Scheff S.W. Synapse loss in frontal cortex biopsies in Alzheimer's disease: correlation with cognitive severity. Ann. Neurol. 1990, 27:457-464.
17. Deshpande A., Win K.M., Busciglio J. Tau isoform expression and regulation in human cortical neurons. FASEB J. 2008, 22:2357-2367.
18. Dolan D., Troncoso J., Resnick S.M., Crain B.J., Zonderman A.B., O'Brien R.J. Age, Alzheimer's disease and dementia in the Baltimore Longitudinal Study of Ageing. Brain 2010, 133:2225-2233.
19. Fahnestock M. Brain-derived neurotrophic factor: the link between amyloid-β and memory loss. Future Neurol. 2011, 6:627-639.
20. Fahnestock M., Marchese M., Head E., Pop V., Michalski B., Milgram W.N., Cotman C.W. BDNF increases with behavioral enrichment and an antioxidant diet in the aged dog. Neurobiol. Aging 2012, 33:546-554.
21. Fahnestock M., Michalski B., Xu B., Coughlin M.D. The precursor pro-nerve growth factor is the predominant form of nerve growth factor in brain and is increased in Alzheimer's disease. Mol. Cell Neurosci. 2001, 18:210-220.
22. Ferrer I., Marín C., Rey M.J., Ribalta T., Goutan E., Blanco R., Tolosa E., Martí E. BDNF and full-length and truncated TrkB expression in Alzheimer disease. Implications in therapeutic strategies. J. Neuropathol. Exp. Neurol. 1999, 58:729-739.
23. Garzon D., Yu G., Fahnestock M. A new brain-derived neurotrophic factor transcript and decrease in brain-derived neurotrophic factor transcripts 1, 2 and 3 in Alzheimer's disease parietal cortex. J. Neurochem. 2002, 82:1058-1064.
24. Garzon D.J., Fahnestock M. Oligomeric amyloid decreases basal levels of brain-derived neurotrophic factor (BDNF) mRNA via specific downregulation of BDNF transcripts IV and V in differentiated human neuroblastoma cells. J. Neurosci. 2007, 27:2628-2635.
25. Ginsberg S.D., Che S., Counts S.E., Mufson E.J. Shift in the ratio of three-repeat tau and four-repeat tau mRNAs in individual cholinergic basal forebrain neurons in mild cognitive impairment and Alzheimer's disease. J. Neurochem. 2006, 96:1401-1408.
26. Ginsberg S.D., Che S., Wuu J., Counts S.E., Mufson E.J. Downregulation of trk but not p75NTR gene expression in single cholinergic basal forebrain neurons mark the progression of Alzheimer's disease. J. Neurochem. 2006, 97:475-478.
27. Goedert M., Jakes R. Expression of separate isoforms of human tau protein: correlation with the tau pattern in brain and effects on tubulin polymerization. EMBO J. 1990, 9:4225-4230.
28. Goedert M., Spillantini M.G., Jakes R., Rutherford D., Crowther R.A. Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease. Neuron 1989, 3:519-526.
29. Goedert M., Wischik C.M., Crowther R.A., Walker J.E., Klug A. Cloning and sequencing of the cDNA encoding a core protein of the paired helical filament of Alzheimer disease: identification as the microtubule-associated protein tau. Proc. Natl. Acad. Sci. U. S. A. 1988, 85:4051-4055.
30. Gold G., Bouras C., Kovari E., Canuto A., Glaría B.G., Malky A., Hof P.R., Michel J.P., Giannakopoulos P. Clinical validity of braak neuropathological staging in the oldest-old. Acta Neuropathol. (Berl) 2000, 99:579-582. discussion 83-84.
31. Gong Y., Chang L., Viola K.L., Lacor P.N., Lambert M.P., Finch C.E., Krafft G.A., Klein W.L. Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:10417-10422.
32. Goode B.L., Chau M., Denis P.E., Feinstein S.C. Structural and functional differences between 3-repeat and 4-repeat tau isoforms. Implications for normal taufunction and the onset of neurodegenetative disease. J. Biol. Chem. 2000, 275:38182-38189.
33. Guillozet-Bongaarts A.L., Garcia-Sierra F., Reynolds M.R., Horowitz P.M., Fu Y., Wang T., Cahill M.E., Bigio E.H., Berry R.W., Binder L.I. Tau truncation during neurofibrillary tangle evolution in Alzheimer's disease. Neurobiol. Aging 2005, 26:1015-1022.
34. Haroutunian V., Schnaider-Beeri M., Schmeidler J., Wysocki M., Purohit D.P., Perl D.P., Libow L.S., Lesser G.T., Maroukian M., Grossman H.T. Role of the neuropathology of Alzheimer disease in dementia in the oldest-old. Arch. Neurol. 2008, 65:1211-1217.
35. Hock C., Heese K., Hulette C., Rosenberg C., Otten U. Region-specific neurotrophin imbalances in Alzheimer disease: decreased levels of brain-derived neurotrophic factor and increased levels of nerve growth factor in hippocampus and cortical areas. Arch. Neurol. 2000, 57:846-851.
36. Holsinger R.M., Schnarr J., Henry P., Castelo V.T., Fahnestock M. Quantitation of BDNF mRNA in human parietal cortex by competitive reverse transcription-polymerase chain reaction: decreased levels in Alzheimer's disease. Brain Res. Mol. Brain Res. 2000, 76:347-354.
37. Hong M., Zhukareva V., Vogelsberg-Ragaglia V., Wszolek Z., Reed L., Miller B.I., Geschwind D.H., Bird T.D., McKeel D., Goate A., Morris J.C., Wilhelmsen K.C., Schellenberg G.D., Trojanowski J.Q., Lee V.M. Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP-17. Science 1998, 282:1914-1917.
38. Kapaki E.N., Paraskevas G.P., Tzerakis N.G., Sfagos C., Seretis A., Kararizou E., Vassilopoulos D. Cerebrospinal fluid tau, phospho-tau181 and beta-amyloid1-42 in idiopathic normal pressure hydrocephalus: a discrimination from Alzheimer's disease. Eur. J. Neurol. 2007, 14:168-173.
39. Kawarabayashi T., Younkin L.H., Saido T.C., Shoji M., Ashe K.H., Younkin S.G. Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J. Neurosci. 2001, 21:372-381.
40. Kawas C.H. Alzheimer's and dementia in the oldest old: a century of challenges. Curr. Alzheimer Res. 2006, 3:411-419.
41. Kawas C.H., Kim R.C., Sonnen J.A., Bullain S.S., Trieu T., Corrada M.M. Multiple pathologies are common and related to dementia in the oldest-old: The 90+ Study. Neurology 2015, 85:535-542.
42. Kawas C.H., Segal J., Stewart W.F., Corrada M., Thal L.J. A validation study of the Dementia Questionnaire. Arch. Neurol. 1994, 51:901-906.
43. Kosik K.S., Orecchio L.D., Bakalis S., Neve R.L. Developmentally regulated expression of specific tau sequences. Neuron 1989, 2:1389-1397.
44. Kuo Y.M., Emmerling M.R., Vigo-Pelfrey C., Kasunic T.C., Kirkpatrick J.B., Murdoch G.H., Ball M.J., Roher A.E. Water-soluble Abeta (N-40, N-42) oligomers in normal and Alzheimer disease brains. J. Biol. Chem. 1996, 271:4077-4081.
45. Lee H.G., Castellani R.J., Zhu X., Perry G., Smith M.A. Amyloid-beta in Alzheimer's disease: the horse or the cart? Pathogenic or protective?. Int. J. Exp. Pathol. 2005, 86:133-138.
46. Lee V.M., Goedert M., Trojanowski J.Q. Neurodegenerative tauopathies. Annu. Rev. Neurosci. 2001, 24:1121-1159.
47. Lesné S., Koh M.T., Kotilinek L., Kayed R., Glabe C.G., Yang A., Gallagher M., Ashe K.H. A specific amyloid-beta protein assembly in the brain impairs memory. Nature 2006, 440:352-357.
48. Lewis S.A., Wang D.H., Cowan N.J. Microtubule-associated protein MAP2 shares a microtubule binding motif with tau protein. Science 1988, 242:936-939.
49. Li J., Gould T.D., Yuan P., Manji H.K., Chen G. Post-mortem interval effects on the phosphorylation of signaling proteins. Neuropsychopharmacology 2003, 28:1017-1025.
50. Lu B., Nagappan G., Lu Y. BDNF and synaptic plasticity, cognitive function, and dysfunction. Handbook Exp. Pharmacol. 2014, 220:223-250.
51. Luberg K., Wong J., Weickert C.S., Timmusk T. Human TrkB gene: novel alternative transcripts, protein isoforms and expression pattern in the prefrontal cerebral cortex during postnatal development. J. Neurochem. 2010, 113:952-964.
52. Matsuo E.S., Shin R.W., Billingsley M.L., Van deVoorde A., O'Connor M., Trojanowski J.Q., Lee V.M. Biopsy-derived adult human brain tau is phosphorylated at many of the same sites as Alzheimer's disease paired helical filament tau. Neuron 1994, 13:989-1002.
53. McDonald J.M., Savva G.M., Brayne C., Welzel A.T., Forster G., Shankar G.M., Selkoe D.J., Ince P.G., Walsh D.M. The presence of sodium dodecyl sulphate-stable Abeta dimers is strongly associated with Alzheimer-type dementia. Brain 2010, 133:1328-1341. Medical Research Council Cognitive Function and Ageing Study.
54. McMillan P., Korvatska E., Poorkaj P., Evstafjeva Z., Robinson L., Greenup L., Leverenz J., Schellenberg G.D., D'Souza I. Tau isoform regulation is region- and cell-specific in mouse brain. J. Comp. Neurol. 2008, 511:788-803.
55. Michalski B., Fahnestock M. Pro-brain-derived neurotrophic factor is decreased in parietal cortex in Alzheimer's disease. Brain Res. Mol. Brain Res. 2003, 111:148-154.
56. Mirra S.S., Heyman A., McKeel D., Sumi S.M., Crain B.J., Brownlee L.M., Vogel F.S., Hughes J.P., van Belle G., Berg L. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991, 41:479-486.
57. Murer M.G., Yan Q., Raisman-Vozari R. Brain-derived neurotrophic factorin the control human brain, and in Alzheimer's disease and Parkinson's disease. Prog. Neurobiol. 2001, 63:71-124.
58. Nagahara A.H., Merrill D.A., Coppola G., Tsukada S., Schroeder B.E., Shaked G.M., Wang L., Blesch A., Kim A., Conner J.M., Rockenstein E., Chao M.V., Koo E.H., Geschwind D., Masliah E., Chiba A.A., Tuszynski M.H. Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease. Nat. Med. 2009, 15:331-337.
59. Nagy Z., Esiri M.M., Jobst K.A., Morris J.H., King E.M., McDonald B., Litchfield S., Smith A., Barnetson L., Smith A.D. Relative roles of plaques and tangles in the dementia of Alzheimer's disease: correlations using three sets of neuropathological criteria. Dementia 1995, 6:21-31.
60. Nelson P.T., Jicha G.A., Schmitt F.A., Liu H., Davis D.G., Mendiondo M.S., Abner E.L., Markesbery W.R. Clinicopathologic correlations in a large Alzheimer disease center autopsy cohort: neuritic plaques and neurofibrillary tangles "do count" when staging disease severity. J. Neuropathol. Exp. Neurol. 2007, 66:1136-1146.
61. Oka T., Tagawa K., Ito H., Okazawa H. Dynamic changes of the phosphoproteome in postmortem mouse brains. PLoS One 2011, 6:e21405.
62. Peng S., Wuu J., Mufson E.J., Fahnestock M. Precursor form of brain-derived neurotrophic factor and mature brain-derived neurotrophic factor are decreased in the pre-clinical stages of Alzheimer's disease. J. Neurochem. 2005, 93:1412-1421.
63. Phillips H.S., Hains J.M., Armanini M., Laramee G.R., Johnson S.A., Winslow J.W. BDNF mRNA is decreased in the hippocampus of individuals with Alzheimer's disease. Neuron 1991, 7:695-702.
64. Robinson J.L., Geser F., Corrada M.M., Berlau D.J., Arnold S.E., Lee V.M., Kawas C.H., Trojanowski J.Q. Neocortical and hippocampal amyloid-β and tau measures associate with dementia in the oldest-old. Brain 2011, 134:3708-3715.
65. Robinson J.L., Molina-Porcel L., Corrada M.M., Raible K., Lee E.B., Lee V.M., Kawas C.H., Trojanowski J.Q. Perforant path synaptic loss correlates with cognitive impairment and Alzheimer's disease in the oldest-old. Brain 2014, 137:2578-2587.
66. Rozen S., Skaletsky H. Primer3 on the WWW for general users and for biologist programmers. Methods Mol. Biol. 2000, 132:365-386.
67. Savaskan E., Müller-Spahn F., Olivieri G., Bruttel S., Otten U., Rosenberg C., Hulette C., Hock C. Alterations in trk A, trk B and trk C receptor immunoreactivities in parietal cortex and cerebellum in Alzheimer's disease. Eur. Neurol. 2000, 44:172-180.
68. Savva G.M., Wharton S.B., Ince P.G., Forster G., Matthews F.E., Brayne C. Age, neuropathology, and dementia Medical Research Council Cognitive Function and Ageing Study. N. Engl. J. Med. 2009, 360:2302-2309.
69. Siegel G.J., Chauhan N.B. Neurotrophic factors in Alzheimer's and Parkinson's disease brain. Brain Res. Brain Res. Rev. 2000, 33:199-227.
70. Steinerman J.R., Irizarry M., Scarmeas N., Raju S., Brandt J., Albert M., Blacker D., Hyman B., Stern Y. Distinct pools of beta-amyloid in Alzheimer disease-affected brain: a clinicopathologic study. Arch. Neurol. 2008, 65:906-912.
71. Stoilov P., Castren E., Stamm S. Analysis of the human TrkB gene genomic organization reveals novel TrkB isoforms, unusual gene length, and splicing mechanism. Biochem. Biophys. Res. Commun. 2002, 290:1054-1065.
72. Tremblay C., Pilote M., Phivilay A., Emond V., Bennett D.A., Calon F. Biochemical characterization of Abeta and tau pathologies in mild cognitive impairment and Alzheimer's disease. J. Alzheimers Dis 2007, 12:377-390.
73. Vanmechelen E., Vanderstichele H., Davidsson P., Van Kerschaver E., Van Der Perre B., Sjögren M., Andreasen N., Blennow K. Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci. Lett. 2000, 285:49-52. 5.
74. Wong J., Higgins M., Halliday G., Garner B. Amyloid beta selectively modulates neuronal TrkB alternative transcript expression with implications for Alzheimer's disease. Neuroscience 2012, 210:363-374.
75. Yamada K., Nabeshima T. Brain-derived neurotrophic factor/TrkB signaling in memory processes. J. Pharmacol. Sci. 2003, 91:267-270.